Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Can-Fite BioPharma Ltd. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 12 | 12 | 0 |
| Shares | 459.3K | 1.46M | +1.00M (+218.4%) |
| Value | $1.05M | $2.43M | +$1.38M (+131.7%) |
New holders (4)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Armistice Capital, LLC | 875,000 | $1.45M | 0.04% |
| Acadian Asset Management LLC | 114,807 | $189.0K | 0.00% |
| Renaissance Technologies LLC | 93,405 | $155.0K | 0.00% |
| Fifth Third Bancorp | 30,000 | $50.0K | 0.00% |
Sold out (4)
Institutions that held Can-Fite BioPharma Ltd. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| StoneX Group Inc. | 40,000 | $91.0K |
| Citadel Advisors LLC | 38,623 | $88.0K |
| Two Sigma Securities, LLC | 10,179 | $23.0K |
| UBS Group AG | 7,709 | $18.0K |